The global Liver Fibrosis Treatment Market was worth US$ 16.43 Billion in 2022 and is expected to reach US$ 46.65 Billion by the year 2033 at a staggering CAGR of 11% between 2023 and 2033.
Liver fibrosis isn’t a typical condition. It’s instead a symptom of a liver disorder. The healthcare professionals are into emphasizing treatment of liver fibrosis by either slowing down or stopping liver’s scarring.
The risk factors linked with liver fibrosis management include autoimmune hepatitis, chronic alcoholism, disorders related to metabolism and storage like Galactosemia, Wilson disease, glycogen storage diseases, Gaucher disease, Fructosemia, iron-overload symptoms, and certain viral, parasitic infections. These diseases do affect hepatic blood flow.
Act Now: Gain Exclusive Insights into the Rising Market Value of Liver Fibrosis Treatment Market – Download Our Sample Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-16529
Liver fibrosis treatment market is actually witnessing an exponential pace in NASH (Non-alcoholic Steatohepatitis) treatment.
Several private research organizations are into research pertaining with development of treatment regarding liver fibrosis with the other fatty liver disease. This factor is expected to take the liver fibrosis treatment market by storm in the forecast period. The US FDA, in April 2019, did approve Mavyret (by AbbVie) as the very first treatment confirmed for the pediatric Hepatitis C patients of every genotype.
At the same time, exorbitant costs involved in liver fibrosis treatment could hamper the liver fibrosis treatment market. The Centers for Disease Analysis states that the US alone invests US$ 5 Billion every single year on disease-related healthcare-related costs like hospitalizations, screening, transplants, and chemotherapy.
As per the National Institute of Health, NAFLD (nonalcoholic fatty liver disease) does represent liver disease that is the most prevalent one; accounting for 25% of cases at global level. NAFLD has its variant called nonalcoholic steatohepatitis, which does influence 5% of those based out of the US.
If you have any questions, feel free to reach out to our analyst @ https://www.futuremarketinsights.com/ask-question/rep-gb-16529
Future Market Insights has entailed these facts with future perspectives in its latest market study entitled ‘Liver Fibrosis Treatment Market’. It has its team of analysts and consultants to deploy a bottom-up approach in its primary, secondary, and tertiary modes of research.
“With growing incidences of liver disorders, the global liver fibrosis treatment market is expected to grow on an unprecedented note going forward”, says an analyst from Future Market Insights.
Key Takeaways from Liver Fibrosis Treatment Market
- North America holds the largest market share with a plethora of drug molecules available for improving treatment process with technological development in this region’s rehabilitation. Also, the key participants are into increasingly spending on healthcare. Also, the fact that NAFLD (Non-Alcoholic Fatty Liver Disorder) ends up affecting close to 20% of Canadians can’t be let off.
- The Asia-Pacific is expected to grow at the quickest rate in the liver fibrosis treatment market on the back of advancements in the medical infrastructure in countries like India, China, and the other South-East Asian economies. Also, there is a growing pool of people contracting Hepatitis C herein.
Competitive Treatment
- Aligos Therapeutics Inc., in December 2020, did enter into collaboration with Merck & Co. Inc. for creating a therapy regarding liver fibrosis treatment.
- Gilead Sciences Inc., in March 2019, did launch HepConnect Program for reducing Hepatitis C Infections in ‘Greater Appalachia’.
- Beijing Continent Pharmaceutical Co., Ltd., in January 2022, upgraded clinical trial regarding Hydronidone capsules to phase 3. It had finished with an effective Phase II clinical trial in December 2021. The Phase III trial is expected to be completed in June 2024.
- HepC, under its vector scheme, has its non-pathogenic double-stranded RNA virus behave as one of the expert inducers of anti-viral gene reactions. It is into development of HC001 for curing chronic viral hepatitis caused due to HCV and HBV infections.
Exclusive Customizations Available: Request Tailored Insights to Outperform in the Liver Fibrosis Treatment Market @ https://www.futuremarketinsights.com/customization-available/rep-gb-16529
What does the Report say?
- The research study is based on treatment type (Peroxisome Proliferator-activated Receptors (PPAR)-alpha agonist, ACE inhibitors, hepatotropic drug, and likewise), condition (chronic liver diseases, Hepatitis C, and non-alcoholic steatohepatitis), and end-user (hospitals, specialty clinics, and likewise).
- With fatalities out of cirrhosis of liver on the rise, the global liver fibrosis treatment market is bound to grow on an astonishing note going forward.
Key Companies Profiled:
- Gilead Sciences, Inc.
- Merck & Co., Inc.
- Bristol-Myers Squibb
- Johnson and Johnson
- Novartis AG
- Vertex Pharmaceuticals Incorporated
- Pfizer Inc.
- FibroGen, Inc.
- Inventiva Pharma
- Pharmaxis Limited
Key Segments Profiled in the Liver Fibrosis Treatment Industry Survey
By Treatment Type:
- Peroxisome Proliferator-activated Receptors (PPAR)-alpha agonist
- ACE Inhibitors
- Hepatotropic Drug
- Others
Act Now to Explore In-Depth Market Analysis: Get Exclusive Purchase Now to Access @ https://www.futuremarketinsights.com/checkout/16529
By Condition:
- Chronic Liver Diseases
- Hepatitis C
- Nonalcoholic Steatohepatitis
By End User:
- Hospitals
- Specialty Clinics
- Others
By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
